Search results
Showing 16 to 30 of 58 results for tuberculosis"
Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)
This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includes measures to prevent and control infection that can stop people needing antimicrobials or spreading infection to others. It aims to change people’s behaviour to reduce antimicrobial resistance and the spread of resistant microbes.
This guideline covers using psychosocial interventions to treat adults and young people over 16 who have a problem with or are dependent on opioids, stimulants or cannabis. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.
from countries with a high prevalence of infectious diseases such as tuberculosis (examples include South Asia and sub-Saharan Africa)....
Infliximab for treating moderate to severe plaque psoriasis (TA134)
Evidence-based recommendations on infliximab for treating moderate to severe psoriasis in adults.
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Infliximab for acute exacerbations of ulcerative colitis (TA163)
Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.
Adalimumab for treating moderate to severe plaque psoriasis (TA146)
Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.
What effects does isolation have on the quality of life of people being treated for TB?
reported. Source guidance details Comes from guidance Tuberculosis Number NG33 Date issued January 2016 Other
For isoniazid-resistant TB, what is the most effective regimen for reducing mortality andmorbidity?
events. Source guidance details Comes from guidance Tuberculosis Number NG33 Date issued January 2016 Other
response. Source guidance details Comes from guidance Tuberculosis Number NG33 Date issued January 2016 Other
useful. Source guidance details Comes from guidance Tuberculosis Number NG33 Date issued January 2016 Other
this area. Source guidance details Comes from guidance Tuberculosis Number NG33 Date issued January 2016 Other
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.